← Back to headlines
Halozyme Therapeutics Misses EPS, Beats Revenue Estimates
Halozyme Therapeutics reported a non-GAAP EPS of -$0.24, missing estimates, but its revenue of $451M surpassed expectations.
17 Feb, 21:04 — 17 Feb, 21:04
ℹOnly 1 source covers this story
